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CYTOTOXIC EFFECTS OF METHYLGERAMBULLIN AND BIS­
(METHYLTHIOMETHYL)-DISULPHIDE (SB) ON T -L YMPHOBLASTIC 
LEUKEMIC CELL LINE (CEM-SS) 
By 
SHAR MARIAM MOHAMED 
August 2000 
Chairman: Associate Professor Abdul Manaf Ali, Ph.D. 
Faculty: Food Science and Biotechnology 
The cytotoxic effects of 2 sulphur-containing compounds were studied on T-
lymphoblastic leukemic cell line. Methylgerambullin is believed to be a new 
sulphone derived from a methylthiopropenoic acid isolated from Glycosmis 
calcicola (family Rutaceae). Another sui phonic compound IS bis-
(methylthiomethyl)-disulphide, an extract from Scorodocarpus borneensis 
(family Olacaceae) with irritating garlic-like odor. Cytotoxic activities of 
methylgerambullin and bis-(methylthiomethyl)-disulphide were tested against 
CEM-SS (T-Iymphoblastic leukaemia), KU812F (chronic myelogeneous 
leukaemia), UACC-62 (melanoma) and HT29 (colon cancer) cell lines using 
MTT, a colorimetric tetrazolium-based assay. Cytotoxic concentrations of the 
compounds that killed cells by 50% (CD50) with respect to untreated cell 
population, varied among the cell lines tested. CEM-SS was found to be the most 
sensitive cell line to methylgerambullin and bis-(methylthiomethyl)-disulphide 
with CD50 = 0.25 )lg/ml and 3.50 )lg/ml respectively. The cytotoxic effects 
exerted by both compounds on this cell line was studied from both morphological 
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manner over 72 hours period. Microscopic observations, including inverted 
microscopy of live cultures, fluorescent microscopy of acridine orange-propidium 
iodide stained cultures, and scanning and transmission electron microscopy 
showed that both necrotic and apoptotic death occurred in meiliylgerambullin­
and bis-(methylthiomethyl)-disulphide-treated cell populations, based on 
morphological criteria. From agarose gel electrophoresis and quantitative 
analyses of intemucleosomal cleavage, treatments with these compounds at their 
respective CD50 doses did not yield random or multiple of 180-200 bp DNA 
fragmentation which often associated with necrotic and apoptotic deaths 
respectively. Such observation may simply owe to the fact that the percentage of 
apoptosis and necrosis events were fairly low as quantified after acridine orange­
propidium iodide staining, or may also suggest the involvement of sulphur 
residue in methylgerambullin and bis-(methylthiomethyl)-disulphide which act as 
an antioxidant, thus protecting DNA degradation from occuring. Flow cytometric 
analyses based on annexin V-FITC (fluorescein isothiocynate) binding to the 
phosphatidylserines residue which was translocated from the inner to the outer 
leaflet of the plasma membrane showed that the onset of apoptosis in both 
methylgerambullin- and bis-(methylthiomethyl)-disulphide-treated population 
was at 6 hours exposure. Both methylgerambullin and bis-(methylthiomethyl)­
disulphide induced GO/G 1 arrest up to 48 hours and 24 hours respectively 
followed by arrest in the subsequent S phase. 
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Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai 
memenuhi keperluan untuk ijazah Doktor Falsafah. 
KESAN SITOTOKSIK OLEH METHYLGERAMBULLIN AND BIS­
(METHYLTHIOMETHYL)�DISULPHIDE (SB) KE ATAS SEL-SEL T­
LIMFOBLASTIK LEUKEMIA (CEM-SS) 
Oleh 
SHAR MARIAM MOHAMED 
Ogos 2000 
Pengerusi: Profesor Madya Dr. Abdul Manaf Ali 
Fakulti: Sains Makanan dan Bioteknologi 
Kesan sitotoksik oleh 2 sebatian yang mengandungi sulfur telah dikaji ke atas sel-
sel T-limfoblastik leukemia. Metilgerambullin, dipercayai satu sebatian sulfon 
yang terbaru ditemui adalah hasilan terbitan daripada asid metiltiopropenoik yang 
diekstrak daripada Glycosmis calcicola (keluarga Rutaceae). Satu lagi sebatian 
ialah bis-(metiltiometil)-disulfida yang diekstrak daripada Scorodocarpus 
borneensis (keluarga Olacaceae) yang berbau seperti bawang putih. Aktiviti 
sitotoksik metilgerambullin dan bis-(metiltiometil)-disulfida telah diuji ke atas 
sel-sel CEM-SS (T-limfoblastik leukemia), KU812F (kronik myelogeneous 
leukemia), UACC-62 (melanoma) dan HT29 (kanser kolon) menggunakan 
kaedah MTT yang bergantung kepada perubahan wama tetrazolium. Hasil kajian 
menunjukkan bahawa sel CEM-SS adalah sel yang paling sensitif terhadap 
metilgerambullin dan bis-(metiltiometil)-disulfida dengan kepekatan yang 
berupaya membunuh 50% daripada populasi sel (CD50) iaitu 0.25 Ilg!ml bagi 
metilgerambullin dan 3.50 Ilg!ml bagi bis-(metiltiometil)-disulfida. Kesan 
sitotoksik sebatian-sebatian ini dinilai melalui perubahan pada morfologi sel dan 
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perubahan di peringkat molekular selepas rawatan dengan sebatian-sebatian 
tersebut selama 72 jam. Penilaian mikroskopik termasuklah menggunakan 
mikroskop terbalikan ke atas kultura hidup, mikroskop floresen selepas 
pewamaan sel dengan akridin oren- propidium iodida dan mikroskopi elektron 
menunjukkan bahawa kematian apoptosis dan nekrosis berlaku di dalam populasi 
sel yang dirawat dengan metilgerambullin dan bis-(metiltiometil)-disulfida. 
Daripada keputusan yang diperolehi melalui elektroforesis pada jel agaros dan 
analisis kuantitatif pada belahan nukleosom, rawatan dengan kedua-dua sebatian 
pada dos CD50 masing-masing tidak menghasilkan belahan rawak atau belahan 
spesifik 180-200 bp pada DNA yang masing-masing dikaitkan dengan kematian 
nekrosis dan apoptosis. Pemerhatian tersebut mungkin disebabkan oleh peratusan 
kematian apoptosis dan nekrosis yang terlalu sedikit sepertimana yang telah 
dikenalpasti secara kuatitatif melalui kaedah pewamaan sel dengan akridin oren 
dan propidium iodida, atau mungkin disebabkan oleh kesan perlindungan sulfur 
yang terdapat pada methylgerambullin dan bis-(metiltiometil)-disulfida yang 
bertindak sebagai antioksidan yang melindungi daripada berlakunya belahan 
DNA. Analisis menggunakan flow saitometer berdasarkan pada ikatan annexin 
V-FITC (fluoresen isotiosianida) pada fosfatidilserine yang mengalami 
translokasi dari lapisan dalam ke lapisan luar membran plasma, menunjukkan 
bahawa kejadian apoptosis dalam populasi sel yang dirawat dengan 
methylgerambullin dan SB berlaku seawal 6 jam selepas rawatan. 
Methylgerambullin dan SB juga didapati berupaya merencatkan sel pada fasa 
GO/G 1 dalam kitaran sel hingga 48 jam dan 24 jam masing-masing selepas 
rawatan, diikuti dengan rencatan pasa fasa S dalam kitaran sel. 
VI 
ACKNOWLEDGEMENTS 
I would like to especially thank my supervisor, Associate Professor Dr. Abdul 
Manaf Ali for his help, guidance, encouragement, critism and patience, without 
whom I would not be able to go through my research years successfully. Above 
all, thank you so much for being so generous with ideas. My utmost appreciation 
to my supervisory committee members, Associate Professor Dr. Mawardi 
Rahmani, Dr. Jasbir S. Dhaliwal and Dr. Raha Abdul Rahim for being very 
helpful throughout my research years. 
For kindly allowing me to use all the facilities within the Faculty of Food Science 
and Biotechnology, I thank the Dean, Professor Dr. Gulam Rasul Rahmat Ali. To 
all the staffs of the faculty, thank you so much for the technical assistance given. 
Not forgetting the Universiti Putra Malaysia, I am truly grateful for the financial 
support from which I was able to complete my research work successfully. 
I gratefully acknowledge the following people for their time, advice and generous 
contributions for making this piece of work possible: staffs of the Electron 
Microscopy Unit, Faculty of Veterinary Medicine; staffs of the Immunology 
Division, Institute for Medical Research Kuala Lumpur especially Mr. Ong, Mr. 
Quek, Kak Zaitun and Kak Zuraidah; Dr. Leong Kah Ho from Becton Dickinson; 
and last but not least the staffs of Makmal Penyelidikan Pusat such as Kak 
Fadillah and Kak Liza. To my fellow Animal Cell Culture Lab colleagues; Tony, 
Lim, Khor, Kak Niza, Kak Siti, Yih Yih, and all my juniors, thanks a zillion for 
sharing the work load of keeping the lab tidy with me (you know I got a little 
VII 
upset once in a while when the contaminants were not discarded properly). To 
have the wonderful opportunity to work with you guys and to experience the 
enjoyable moments is an everlasting souvenir that I will always cherish. 
V1l1 
I certify that an Examination Committee met on 28 August 2000 to conduct the 
final examination of Shar Mariam Mohamed on her Doctor of Philosophy thesis 
entitled "Cytotoxic Effects of Methylgerambullin and Bis-(methylthiomethyl)­
disulphide (SB) on T-Lymphoblastic Leukemic Cell Line (CEM-SS)" in 
. accordance with Universiti Pertanian Malaysia (Higher Degree) Act 1980 and 
Universiti Pertanian Malaysia (Higher Degree) Regulations 1981. The Committee 
recommends that the candidate be awarded the relevant degree. Members of the 
Examination Committee are as follows: 
Professor Suhaila Mohamed, Ph.D, 
Faculty of Food Science and Biotechnology, 
Universiti Putra Malaysia 
( Chairperson) 
Associate Professor Abdul Manaf Ali, Ph.D, 
Faculty of Food Science and Biotechnology, 
Universiti Putra Malaysia 
(Member) 
Associate Professor Mawardi Rahmani, Ph.D, 
Faculty of Environmental Science, 
Universiti Putra Malaysia 
(Member) 
Raha Abdul Rahim, Ph.D, 
Faculty of Food Science and Biotechnology, 
Universiti Putra Malaysia 
(Member) 
Jasbir S. Dhaliwal, Ph.D, 
Division of Immunology, 
Institute for Medical Research, Kuala Lumpur 
(Member) 
Professor Peter 1. Houghton, Ph.D, 
King's College of London 
(Independent Examiner) 
. GHAZALI MOHA YIDIN, Ph.D. 
Pro essorlDeputy Dean of Graduate School, 
Universiti Putra Malaysia 
Date: 0 1 NOV 2000 
IX 
This thesis submitted to the Senate of Universiti Putra Malaysia and was accepted 
as fulfilment of the requirements for the degree of Doctor of Philosophy. 
x 
KAMIS A WANG, Ph.D, 
Associate Professor 
Dean of Gradute School, 
Universiti Putra Malaysia 
Date: 14 DEC 2000 
DE CLARA TION 
I hereby declare that the thesis is based on my original work except for quotations 
and citations which have been duly acknowledged. I also declare that it has not 
been previously or concurrently submitted for any other degree at UPM or other 
institutions. 
Candidate 
SHAR MARIAM MOHAMED 
Date: 25 October 2000 
Xl 
TABLE OF CONTENTS 
Page 
DEDICATION ............................................................................................. ii 
ABSTRACT .................................................................................................. iii 
ABSTRAK .................................................................................................... v 
ACKN"OWLEDGEMENTS ........................................................................ vii 
APPROVAL SHEETS ................................................................................. ix 
DECLARATION ......................................................................................... xi 
LIST OF TABLES ....................................................................................... xv 
LIST OF FIGURES ..................................................................................... xvi 
LIST OF PLATES ....................................................................................... xviii 
LIST OF ABBREVIATIONS ..................................................................... xix 
CHAPTER 
I INTRODUCTION ................................... . ................................ . . ....... 1 
II LITERATURE REVIEW .................................................................. 6 
Sulphur-containing Compounds ........................................................ 6 
Leukemia ..................... .................................................................. ..... 12 
Cell Death 
Nomenclature and Terminology .............. ........... .............. . ........... 15 
Biochemical and Genetic Control of Cell Death ............... ........... 22 
Mitochondria As Damage Sensor and Execution of Cell Death ... 23 
Nuclear Events in Apoptosis ......................................................... 27 
Cell Death and Its Relevance in Animal Development and 
Disease .................. .. ...................................................................... 31 
Apoptosis in Hematopoiesis and Hematological Malignancies .... 33 
Cell Death Detection 
Screening for potential anticancer drugs ......... . ............................. 36 
Microculture Tetrazolium Assay (MTA) ...................................... 36 
Microscopic Analyses .. ............. , .................................................. .40 
Basic Principle of Flow Cytometry ................................................... .44 
The Cell Cycle ....................................................................... 45 
Flow Cytometric Analyses of DNA Content in Human Malignancy 50 
Cell Cycle and Its Significance in Cytotoxicity and Chemotherapy .. 52 
Detection of Apoptosis Using Flow Cytometric Method .................. 55 
III MATERIALS AND METHODS .................. .............................. .... ... 59 
Cell Line ...... ......................................................................... ...... ... .... 59 
Reviving Cells ... ................................................................................. 59 
Storing Cells .............................................. ....................... ..... . ... ... ..... 60 
Cell Line Maintenance 
Suspension Cell Culture ............................................................... 60 
Xll 
Anchorage-dependent Cell Culture ............................................... 60 
Isolation of Human Peripheral Blood Mononuclear Cells ............ 61 
Test Compounds 
Purified Natural Products .............................................................. 61 
Commercial Drugs ........................................................................ 63 
Cytotoxic Assay ................................................................................. 64 
Statistical Analysis ............................................................................. 65 
Proliferation Assay ............................................................................. 65 
Synchronization of Cells .................................................................... 66 
Morphological Analyses 
Giemsa Staining ............................................................................ 66 
Acridine Orange (AO) and Propidium Iodide (PI) Staining ......... 67 
Electron Microscopy ..................................................................... 67 
Molecular Analyses 
DNA Extraction and Analyses for Apoptosis Induction .. ............ 69 
Cell Death Detection ELISA PLUS kit ............................................. 70 
Flow Cytometric Analyses 
Cell Cycle Specificity ................................................................... 71 
Early Apoptosis Detection (Annex in V binding) .......................... 72 
IV RESULTS .......................................................................................... 73 
Cytotoxicity of Test Compounds Against Various Cell Lines ......... 73 
Statistical Analyses ............................................................................ 78 
Proliferative Profiles of CEM-SS After Treatment With Various Test 
Compounds at Their Respective CD50 ............................................. 82 
Cellular Examination 
Determination of CD50 from MTT Assay: Dose-dependent 
Studies ................ . . . . . . . . . . . . . . . . ..... . . . . . . .. . . . . . . . . . . . .......... . . . . . . . . . . . . . . . .......... 84 
Treatment at CD50: Time-dependent Studies .............................. 91 
Effects of Control Drugs on CEM-SS .......................................... 94 
Effects of Methylgerambullin and SB on Peripheral Blood 
Mononuclear Cells ........................................................................ 96 
Fluorescence Microscopy ............................................................. 96 
Giemsa Staining ............................................................................ 1 05 
Electron Microscopy ..................................................................... 1 05 
Progression of Apoptosis Events .................................................. 116 
Progression of Necrosis Events .................................................... 119 
Synchronization of Cells .................................................................... 119 
Effects of Methylgerambullin and SB on Nuclear Fragmentation ..... 121 
Flow Cytometric Analyses 
Detection of Early Apoptosis Events ............................................ 125 
Cell Cycle Analyses ...................................................................... 135 
V DISCUSSION .................................................................................... 152 
Cytotoxic, Proliferative and Resistance Profiles of Test 
Compounds ........................................................................................ 152 
Xlll 
Proliferative Profiles of CEM-SS After Treatment With Test 
Compounds ........................................................................................ 156 
Effects of Methylgerambullin and SB on Cell Morphology .............. 162 
Effects of Methylgerambullin and SB on Nuclear Fragmentation ..... 173 
Flow Cytometry: Detection of Apoptosis . . ........................................ 182 
Flow Cytometry: Cell Cycle Analyses ....... .................... .................... 186 
VI CONCLUSION ...................... ........................................ .................... 194 
REFERENCES ............................................................................................. 200 
APPENDICES .............................................................................................. 219 
A Preparation of Media and Solutions ................................................... 220 
B Calculation for Cell Viability and Cell Concentration ...................... 222 
C The Means and Standard Error of Means (SEM) Corresponding to 
Figures 12 and 13 ....... ........................................ ............................... 223 
D Two-ways Analysis of Variance (ANOVA) ...................................... 224 
VITA . ........................................................................................... . ............... 228 
XIV 
LIST OF TABLES 
Table Page 
1 ......... Biochemical determinants of apoptosis and necrosis ........................ 26 
2 ......... Commercial drugs of various classes used as controls in this study. 63 
3 ......... Sensitivity of various cell lines to methylgerambullin and SB ......... 73 
4 ......... Sensitivity of CEM-SS to various commercial drugs . . . . . . .. . . .. . . . . . ..... .  78 
5 ......... Sensitivity of CEM-SS to methylgerambullin, SB and various 
commercial drugs .............................................................................. 80 
6 ......... The percentage of mitotic cells induced by colchicine at different 
concentrations ................................................................................... 121 
7 . . . . . .... The summary of dose-dependent percentage of viable, apoptotic 
and necrotic CEM-SS cells .............................................................. . 129 
8 ......... The summary of time-dependent percentage of viable, apoptotic 
and necrotic CEM-SS cells ............................................................... 134 
9 ......... Cell cycle distribution in CEM-SS after24 hours incubation with 
methylgerambullin, SB, gonoiothalamin, cisplatin, etoposide 
and colchicine at various concentrations ........................................... 144 
10 ....... Cell cycle distribution in CEM-SS after incubation with 
methylgerambullin, SB, gonoiothalamin, cisplatin, etoposide 
and colchicine at CD50 doses for various duration of time .............. 150 
11 ....... Time-dependent cytotoxic profiles of control drugs, methylgerambullin 
and SB against CEM-SS cell line ...................................................... 223 
12 ....... Proliferative profiles of CEM-SS cells after treatment with 
methylgerambullin, SB and control drugs at their respective 
CD50 dose . . . . . . . . . . . . . . . . . . . . . .. . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . ... . . . ....... . . . . .  223 
13 ....... The summary of means of CD50 for different compounds/drugs (Xi) 
and means of CD50 exhibited by different CEM-SS sub-populations 
at different time (Xj) ......................................................................... 224 
14 ....... The summary of two-ways ANOV A. . .. . . . . . . ... . . . . . . ....... . . . . ...... . .. ......... . 225 
xv 
LIST OF FIGURES 
Figure Page 
1 ......... The experimental approach implemented in the current study ......... 5 
2 ......... The structure of methylgerambullin and SB (bis-(methylthiomethyl)-
disulphide) ......................................................................................... 11 
3 ......... Morphological changes during apoptosis and necrosis ..................... 20 
4 ......... Flow diagrams of apoptotic and necrotic major events ..................... 21 
5 ......... Tetrazolium salts and its formazan .................................................... 37 
6 ......... Evolution of tetrazolium salts used in measuring cell viability ........ 38 
7 ......... The cell cycle .................................................................................... 48 
8 ......... Cyclical changes in DNA content of a dividing cell ......................... 49 
9 ......... The percentage of cell viability of various cell lines after treatment with 
different concentrations of methylgerambullin for 72 hours ............ 75 
10 ....... The percentage of cell viability of various cell lines after treatment with 
different concentrations of SB for 72 hours ...................................... 76 
11 ....... The percentage of cell viability of CEM-SS after treatment with different 
concentrations of control drugs, methylgerambullin and SB for 72 
hours74 .............................................................................................. 77 
12 ....... Time-dependent cytotoxic profiles of control drugs, methylgerambullin 
and SB against CEM-SS cell line ...................................................... 81 
13 ....... Proliferative profiles of CEM-SS cell line ........................................ 83 
14 ....... Time-dependent trends of apoptotic and necrotic incidence in CEM-SS 
cell population ................................................................................... 103 
15 ....... Detection of mono- or oligonucleosomal DNA fragmentation in 
methylgerambullin- and SB-treated CEM-SS population by ELISAPLUS 
immunoassay ..................................................................................... 124 
16 ....... Classification of viable, apoptosis and necrosis based on Annexin V -FITC 
and propidium iodide uptake ............................................................. 125 
17 ....... Flow cytometric analyses on detection of apoptosis and necrosis at 
different doses for 24 hours ............................................................... 127 
XVI 
18 ....... Time course flow cytometric analyses on detection of apoptosis and 
necrosis at CD50 doses ..................................................................... 132 
19 ....... Determination of cell cycle statistics from dot plot and histogram using 
CE LLFIT and LYSIS II softwares .................................................... 138 
20 ....... Flow cytometric cell cycle analyses based on DNA content ............ 142 
21 ....... Time-dependent flow cytometric cell cycle analyses based on DNA 
content ............................................................................................... 148 
22 ....... Possible stages in the process of responding to cellular damage ...... 153 
23 ....... Characterization of viable, apoptotic and necrotic cells based on the 
chromatin structure after dual staining with acridine orange and 
propidium iodide ............................................................................... 167 
24 ....... The distribution of means between samples in the hypothesis 
testing ................................... ............................................................. 226 
25 ....... The distribution of means within samples in the hypothesis 
testing ................................................................................................ 226 
XVII 
LIST OF PLATES 
Plate Page 
1 ......... Photomicrographs from inverted microscopy ....... . . .......................... 85 
2 ......... Photomicrographs of cells after the addition ofMTT ....................... 89 
3 ......... Photomicrograph of formazan crystals surrounding viable CE M-SS cells 
detected after 4 hours incubation with MTT ....................... .............. 90 
4 . .. . ..... Time-dependent morphological changes of CE M-SS cells treated with 
methylgerambullin ............................. ........................................ . ...... 92 
5 ......... Time-dependent morphological changes of CEM-SS cells treated 
with SB ......................... .......................................................... , ..... " .. , 93 
6 ......... CE M-SS cells after 72 hours treatment with control drugs ............... 95 
7 ......... Peripheral blood mononuclear cells .................... ............................. . 97 
8 ......... Photomicrographs of acridine-orange-propidium iodide stained CEM-SS 
cells .. , ........ , ... , .......... , ........................ " ............. ,", .. , .... ,.,. , ........... , , ..... 100 
9 ......... Photomicrographs of viable, apoptotic and necrotic cells ... , ............. 102 
10 ....... Giemsa staining ......... . . . . ........... . . . . .................... ......................... . . . ..... 106 
11 . . . ... , Scanning electron micrographs of methylgerambullin-treated CEM-SS 
cells ... " .... ,.,', .......... , ........ , ............. , ..... , .................................. , ........... 109 
12 ....... Scanning electron micrographs of SB-treated CE M-SS cells .......... .  111 
13 ....... Close up view of scanning electron micrographs .............................. 113 
14 ....... Transmission electron micrographs of CEM-SS treated with 
methylgerambullin and SB ............... .................. . . . . . . . ........................ 115 
15 ....... Ultrastructural changes in apoptotic cells ......................................... 117 
16 ... . , .. Ultrastructural changes in necrotic cells ........................................... 120 
17 ....... DNA profiles from agarose gel electrophoresis ........... , ............ , ....... 123 
XVlll 
LIST OF ABBREVIATIONS 
2-CDA ........... chloro deoxyadenosine 
ABTS ............ 2,2' -Azino-di[3-ethylbenzthiazolin-sulfonat] 
ADP ... ........... adenosine diposphate 
AIF. .... ........... apoptosis indusing factor 
ALL ... ........... acute lymphoblastic leukemia 
AML .. . . . . . ... .. .  acute myeloid leukemia 
AO ..... ........... acridine orange 
Ara-c ............. arabinofuranosylcytosine 
ATP .............. adenosine triposphate 
CA ..... ........... calyculin A 
CD50 . ........... cytotoxic dose resulting in 50% reduction of cell population 
CGM .. ........... complete growth medium 
CLL . ... ........... chronic lymphocytic leukemia 
CML ............. chronic myeloid leukemia 
C02 . . . • . • . . . • • . • . •  carbon dioxide 
CV ..... ........... coefficient of variation 
Cyt-c ............. cytochrome c 
DCF ... ........... deoxycorfomycin 
DDS .............. diaminodiphenyl sulphone 
DMSO ........... dimethyl sulfoxide 
DNA .. ........... deoxyribonucleic acid 
ER ...... ........... endoplasmic reticulum 
FDA .............. Food and Drug Administration 
FITC .. ........... fluorescein isothiocyanate 
FSC .... ........... forward scatter 
GSH .............. glutathione 
HCI .... ........... hydrochloric acid 
HIV .... ........... human immunodeficiency virus 
ICAD ............ inhibitor of caspase-activated DNAse 
ICE. ............... interleukin converting enzyme 
KCI .... ........... potassium chloride 
MTT .. ........... 3(4 ,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
MT A . ............ microculture tetrazolium assay 
MTS ... ........... 3-[ 4,5-dimethylthiazol-2-yl]-5-( carboxymethoxyphenyl),( 4-
sulphophenyl)-2H-tetrazolium 
MeOH ........... methanol 
MTP . .. .... . . .. . .. microtiter plate 
NaCI .. ........... sodium chloride 
NHAC ........... N4-hexadecyl-l-p-D-arabinofuranosylcytosine 
OD ..... ........... optical density 
OA ..... ........... okadaic acid 
PARP ............ poly(ADP-ribose) polymerase 
PBMC ........... peripheral blood mononuclear cell 
PBS .... ........... phosphate buffered saline 
Pl ....... ........... propidium iodide 
PMS ... ........... phenazine methosulphate 
XIX 
PMT ... .. ......... photo multiplier 
PS ...... . .. ......... phosphotidylserine 
PT ...... ........... permeability transition 
RNA. .. ........... ribonucleic acid 
RNP ... ........ ... ribonucleoprotein particles 
ROS ... ........ ... reactive oxygen species 
SB ...... ........... bis-(methylthiomethyl)-disulphide isolated from Scorodocarpus 
borneensis Becc. 
SDS .. .. . .. .. ... ... sodium dodecyl sulphate 
SE M . . . ... ... ..... scanning electron microscope 
sse .... ... . . . . .... side scatter 
TE M  . . ..... ...... transmission electron microscope 
TNF . .. .. ...... .. . tumor necrosis factor 
TUNEL ... ....... Tdt-mediated dUTP-biotin nick end labelling 
UV ..... ...... ..... ultraviolet 
XTT ... ........... sodium (2,3-bis[2-methoxy-4-nitro-5-sulphophenyl]-2H­
tetrazolium-5-carboxanilide) 
xx 
CHAPTER I 
INTRODUCTION 
1 
Screening for potential anticancer compounds has been one of the most 
important aspects in cancer research. Many commercially available drugs are 
synthetically derived, for example etoposide, a semi-synthetic 
epipodophyllotoxin that is one of the most commonly used anti-cancer drugs 
(Joel, 1996). Although these synthetic drugs are known to be very effective 
against cancer cells, they also possess some undesirable side effects such as 
neurotoxicity, fibrinolysis and ototoxicity (hearing loss) (Casciato and Lowitz, 
1995). Thus, choices for improvement are confined to introduce natural products 
as potential anticancer agents. Phytochemicals, one of these natural substances 
have been known to exhibit a wide variety of medicinal value ever since the 
ancient times. The scientific theories underlying their medicinal properties 
however remained unknown then. Wilkinson, (1998) recently highlighted that 
herbal products have great potential in the emerging nutraceutical and 
pharmaceutical industries in that they are widely consumed as food and are used 
in preventive and curative treatments throughout the world. It was reported in the 
same study that tropical forests have produced 47 major pharmaceutical drugs of 
world-wide importance and it is estimated that 328 potential drugs of major 
importance is yet to be discovered which would be worth $147 billion. The 
tropical forests still offers 125,000 flowering plant species that are of 
pharmacological relevance but this will involve 50,000 to one million screening 
2 
tests to discover one profitable drug, which seem to be the ultimate constraint in 
the discovery of new drugs. 
It has been reported by the Alliance Pharmaceutical Corporation that on average, 
12 years are needed for an experimental drug to be brought from the laboratory 
to the market shelf (Wierenga and Eaton, Internet). Preclinical testing requires 
three and a half years of experiments in laboratory on in vitro and animal models 
to assess safety and biological activities of the compound. Another six years are 
required for clinical trials that assess the safety, dosage, effectiveness and 
monitor the adverse reaction of the compound. Only five in 5000 compounds that 
enter preclinical testing make it to human testing. Approval process by the Food 
and Drug Administration (FDA) will take about two and a half years where 
normally only one of the five compounds tested in humans is approved. 
Despite the duration of time required to evaluate a potential drug, numerous 
phytochemicals have been scientifically isolated and their discovery was very 
much directed in the perspective of anticancer drug development. Plant 
constituents such as taxol, camptothecin, podophyllotoxin, vinblastine and 
vincristine represent some of the most important drugs currently utilized for the 
treatment of human cancers (Wall and Wani, 1993). Numerous more 
phytochemica1s are under investigations and have the potential to be on the 
pharmaceutical market shelves. Among these are betulinic acid, gonoithalamin 
and dammarane-type triterpenes, to name a few. Betulinic acid, which is 
available in abundant supply from the bark of white birch trees was reported to 
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be specific for inhibiting human melanomas (Pisha et al., 1995). 
Gonoiothalamin, isolated from various Gonoiothalamus sp. was found to be 
toxic to cervical, pancreas, gastric and breast carcinoma (Ali et al., 1996). 
Dammarane-type triterpenes from Cloeme africana has been shown to be highly 
toxic against leukemia (Nagaya et ai., 1997). 
One of the most extensively studied diseases is leukemia that remains to be a 
formidable disease. Due to the ease of obtaining repeated samples from blood, 
marrow or lymph nodes, most of the principles of cancer therapy is largely based 
on the leukemia model. Important breakthroughs in cancer therapy were 
achieved in the treatment of leukemia, which includes the use of combination 
therapy, immunotherapy, supportive therapy using antibiotics and blood product 
support and bone marrow transplant (Ng, 1996). Treatment with antileukaemic 
drugs however only controls the symptom without enhancing the survival rate 
(Arthur, 1989). Chemotherapeutic agents, also known as cytotoxins due to its 
ability to kill cells are normally less specific in that these agents kill not only 
cancer cell but also normal cells. Thus, the most apparent implication of 
chemotherapy is emanation of side effects which include hair loss, nausea, 
vomitting, constipation and can be as disastrous as myelosuppression (drop in 
blood count - neutropenia, thrombocytopenia, anaemia), and damage on cardiac, 
pulmonary, renal and hepatic systems (Ng, 1996). This prompted efforts to 
screen for antileukaemic agents that will have a dramatic cytotoxic effect 
specifically on the target cells. Most of the drugs currently used act via two 
distinct mechanisms: inhibition of cell proliferation or induction of active cell 
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death (Vial et al., 1997). Compounds that act via the latter mechanism are likely 
to be a better candidate as an antileukaemic agent because in the former action, 
some individual cells may have escaped through salvage pathways, and will 
continue to proliferate. The advancement in research techniques and the 
introduction of new molecular tools in recent years have prompted more efforts 
in investigations to build understanding on how exposure to the existing or newly 
discovered drugs lead to cell death. The efficacy of these drugs has been 
critically assessed by the many mechanisms of cell death and resistance that 
adversely limit their efficacy. Today, due to the urgent need for studies in various 
fields that closely mimics the animal systems, animal cell culture which was only 
an esoteric art during those time has become an established technology. New 
drug discovery, for example, may not be recognized and may be unsafe for use in 
man. Thus, pre-clinical trials are needed, which can be made possible with cell 
culture technology. 
It is thus crucial to determine the mode of action exerted by a potential 
anticancer agent. This has led to the design of the experimental approach which 
will be implemented in the current study. Both cellular and molecular changes in 
treated cell populations will be examined and compared with control (untreated) 
populations in a time course manner. Hence, either necrotic or apoptotic cell 
death could be suggested. Morphological studies may offer answers to whether 
physiological and accidental deaths are causally related and to the degree of 
overlapping between apoptotic and necrotic pathways. 
